Autologous Stem Cells ( DrugBank: - )

---

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	3
51	全身性強皮症	1

13. 多発性硬化症／視神経脊髄炎

---

臨床試験数 : 3,342 /  薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04749667 (ClinicalTrials.gov)	August 9, 2021	20/1/2021	Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis	Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis	Multiple Sclerosis;Progressive Multiple Sclerosis	Other: MSCs;Drug: Saline	Haukeland University Hospital	University of Bergen;University Hospital Ulm;University Hospital, Akershus;St. Olavs Hospital;University Hospital of North Norway	Recruiting	18 Years	55 Years	All	18	Phase 1/Phase 2	Norway
2	NCT03829566 (ClinicalTrials.gov)	November 2019	1/2/2019	Autologous Transplant To End NMO Spectrum Disorder	Autologous Hematopoietic Stem Cell Transplant for Neuromyelitis Optica Spectrum Disorder (NMOSD)	Neuromyelitis Optica;Devic's Disease;NMO Spectrum Disorder	Drug: Rituximab;Drug: Cyclophosphamide;Drug: Mesna;Drug: rATG;Drug: Methylprednisolone;Drug: G-CSF;Biological: IVIg;Biological: Autologous Stem Cells	Northwestern University	NULL	Withdrawn	18 Years	65 Years	All	0	Phase 2/Phase 3	United States
3	NCT03342638 (ClinicalTrials.gov)	November 8, 2017	9/11/2017	Maximizing Outcome of Multiple Sclerosis Transplantation	Maximizing Outcome of Multiple Sclerosis Transplantation: MOST Trial	Multiple Sclerosis, Relapsing-Remitting	Drug: Cyclophosphamide;Drug: Mesna;Drug: rATG;Drug: Methylprednisolone;Drug: G-CSF;Biological: IVIg;Biological: Autologous Stem Cells	Northwestern University	NULL	Terminated	18 Years	58 Years	All	66	Phase 3	United States

51. 全身性強皮症

---

臨床試験数 : 523 /  薬物数 : 608 - (DrugBank : 156) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 215

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03593902 (ClinicalTrials.gov)	May 17, 2018	28/6/2018	Cardiac Safe Transplants for Systemic Sclerosis	Autologous Hematopoietic Stem Cell Transplant for Patients With Systemic Sclerosis and Cardiac Dysfunction	Systemic Sclerosis;Scleroderma	Drug: Rituximab;Drug: Fludarabine;Drug: Cyclophosphamide;Drug: Mesna;Drug: rATG;Drug: Methylprednisolone;Drug: G-CSF;Biological: IVIg;Biological: Autologous Stem Cells	Northwestern University	NULL	Terminated	18 Years	65 Years	All	9	Phase 2/Phase 3	United States